Cargando…

The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice

Background and Aims: It’s reported that bone morphogenetic protein 9 (BMP9) played an important role in lipid and glucose metabolism, but the role of BMP9 in nonalcoholic fatty liver disease (NAFLD) is unclear. Here, we evaluated the therapeutic efficacy of recombined BMP9 in NAFLD mice and investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Qin-Juan, Cai, Ling-Yan, Jian, Jie, Cui, Ya-Lu, Huang, Chen-Kai, Liu, Shu-Qing, Lu, Jin-Lai, Wang, Wei, Zeng, Xin, Zhong, Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884862/ https://www.ncbi.nlm.nih.gov/pubmed/33603666 http://dx.doi.org/10.3389/fphar.2020.605967

Ejemplares similares

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

Insights into bone morphogenetic proteins in cardiovascular diseases
por: Ye, Di, et al.
Publicado: (2023)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
por: Wang, Xue-Kai, et al.
Publicado: (2021)

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
por: Li, Hu, et al.
Publicado: (2022)

Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Peng, Sihan, et al.
Publicado: (2022)

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
por: Song, Chong, et al.
Publicado: (2023)

Ilexsaponin A(1) Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism in Mice
por: Zhao, Wen-wen, et al.
Publicado: (2021)

Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
por: Cui, Huantian, et al.
Publicado: (2020)

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
por: He, Xuan, et al.
Publicado: (2023)

Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease
por: Su, Changtian, et al.
Publicado: (2022)

Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2022)

Editorial: Nonalcoholic fatty liver disease: From pathogenesis to phytomedicine based on omics technology
por: Ji, Guang, et al.
Publicado: (2022)

Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis
por: Core, Amanda B., et al.
Publicado: (2014)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2022)

Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice
por: Cui, Yizhe, et al.
Publicado: (2021)

Da-Chai-Hu Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Remodeling the Gut Microbiota and Modulating the Serum Metabolism
por: Cui, Huantian, et al.
Publicado: (2020)

Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins
por: Rivera, Jessica C., et al.
Publicado: (2013)

Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
por: Feng, Yanbo, et al.
Publicado: (2021)

N-Acetyl Cysteine Ameliorates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Intracellular Triglyceride Accumulation by Preserving Mitochondrial Function
por: Hang, Weijian, et al.
Publicado: (2021)

Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis
por: Liang, Wenyi, et al.
Publicado: (2021)

Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease
por: Yang, Keungmo, et al.
Publicado: (2023)

Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism
por: Lu, Yifei, et al.
Publicado: (2022)

Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease: Indications From Mendelian Randomization
por: Li, Shuxuan, et al.
Publicado: (2022)

Editorial: Nonalcoholic fatty liver disease therapy: Exploring molecular mechanisms of well-defined composition from natural plants
por: Zhang, Wenji, et al.
Publicado: (2022)

The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice
por: Vollaire, Julien, et al.
Publicado: (2019)

Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
por: Liu, Yingying, et al.
Publicado: (2022)

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease
por: Pastore, Mirella, et al.
Publicado: (2019)

Osteogenic Enhancement Between Icariin and Bone Morphogenetic Protein 2: A Potential Osteogenic Compound for Bone Tissue Engineering
por: Zhang, Xin, et al.
Publicado: (2019)

In Vitro and In Vivo Osteogenesis Induced by Icariin and Bone Morphogenetic Protein-2: A Dynamic Observation
por: Xie, Lina, et al.
Publicado: (2020)

Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology
por: Liu, Yingying, et al.
Publicado: (2023)

The Role of Bone Morphogenetic Protein Signaling in Non-Alcoholic Fatty Liver Disease
por: Thayer, Timothy E., et al.
Publicado: (2020)

Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
por: Hao, Jianan, et al.
Publicado: (2022)

Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents
por: Xie, Ruijie, et al.
Publicado: (2022)

Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis
por: Wang, Xingchun, et al.
Publicado: (2022)

FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism
por: Zhao, Fanrong, et al.
Publicado: (2022)

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022)

Potential Roles of Bone Morphogenetic Protein (BMP)-9 in Human Liver Diseases
por: Herrera, Blanca, et al.
Publicado: (2014)

Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy
por: Zhang, Qing-Qing, et al.
Publicado: (2015)

Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome
por: Zhang, Huicun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jiinsha0fd94mijlfpsrje5bqo